Altheos, Inc.

Quick facts

Phase 2 pipeline

• ATS907 · Autoimmune diseases
  ATS907 is a small molecule that targets the S1P1 receptor.

Phase 1 pipeline

• Stage 1 - ATS907 - Dose 1

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Altheos, Inc. portfolio CI brief
• Altheos, Inc. pipeline updates RSS